Niki BioSolutions (NIKI) Financials
Ticker history: APM became NIKI (Niki BioSolutions, Inc.) on . Earlier news and filings retain their original names and dates. View APM history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for FY2025, filed May 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NIKI SEC filings page.
This page shows Niki BioSolutions, Inc. (NIKI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Niki BioSolutions, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Niki BioSolutions, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
Niki BioSolutions, Inc. reported a net loss of $1.4M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Niki BioSolutions, Inc. earned -$0.04 per diluted share (EPS) in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Cash & Balance Sheet
Niki BioSolutions, Inc. held $3.5M in cash as of Q4 2025; no long-term debt figure is on record for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
NIKI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, Diluted Shares (Avg).
NIKI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'25Filing | Q3'25Filing | Q2'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q4'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $18.7M+15.9% | $17.6M | $18.1M+2.3% | $16.1M-21.9% | N/A | $17.7M+22.8% | $20.6M-1.1% | $14.4M-40.0% |
| Current Assets | $3.6M+274.4% | $2.5M | $3.0M+95.9% | $960K-61.2% | N/A | $1.5M-19.2% | $2.5M-65.0% | $1.9M-79.6% |
| Cash & Equivalents | $3.5M+295.0% | $2.3M+201.2% | $2.8M+252.1% | $874K-56.4% | $755K | $783K+130.1% | $2.0M-60.0% | $340K-91.6% |
| Short-Term Investments | N/A | $0n/m | $0n/m | N/A | $0 | $0n/m | $0-100.0% | $0n/m |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $22K-67.2% | $48K-72.6% | $66K-7.5% |
| Long-Term Investments | $15.1M0.0% | $15.1Mn/m | $15.1M-6.2% | $15.1M-6.2% | $0 | $16.1M+65.2% | $16.1M+65.2% | $9.7M+12523.0% |
| Total Liabilities | -$4.4Mn/m | -$5.0M | -$5.0Mn/m | -$5.0Mn/m | N/A | -$5.0Mn/m | -$4.2M-181.6% | -$7.4M-641.8% |
| Current Liabilities | $4.6M+5.9% | $4.4M | $1.0M-23.5% | $4.3M+106.7% | N/A | $1.3M-8.2% | $2.1M | $1.4M |
| Non-Current Liabilities | -$9.0Mn/m | -$9.4M | -$6.0Mn/m | -$9.3Mn/m | N/A | -$6.3Mn/m | -$6.3M | -$8.9M |
| Long-Term Debt | N/A | N/A | $3.3M | N/A | N/A | N/A | $3.1M+2255.5% | N/A |
| Total Equity | $23.1M+9.4% | $22.5M | $23.1M+2.1% | $21.1M-14.9% | N/A | $22.7M+3.7% | $24.8M+58.1% | $21.8M-3.5% |
| Retained Earnings | -$73.8Mn/m | -$73.5M | -$72.9Mn/m | -$72.4Mn/m | N/A | -$70.8Mn/m | -$68.2Mn/m | -$70.8Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill.
NIKI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NIKI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Niki BioSolutions, Inc. NIKI | FY2025 | N/A | -$1.4M | N/A | $1.3M | — |
| CDT Equity Inc. CDT | FY2025 | N/A | N/A | N/A | $1.3M | — |
| PMGC Holdings Inc. ELAB | FY2025 | $590K | -$7.7M | N/A | $1.3M | — |
| Karyopharm Therapeutics Inc. KPTI | FY2025 | $146.1M | -$196.0M | N/A | $1.2M | 47/100 |
| Matinas BioPharma Holdings, Inc. MTNB | FY2025 | N/A | -$10.3M | N/A | $1.2M | — |
| Scinai Immunotherapeutics Ltd. SCNI | FY2025 | $1.3M | -$8.3M | N/A | $1.2M | 54/100 |
Where Niki BioSolutions, Inc. Ranks
Frequently Asked Questions
No, Niki BioSolutions, Inc. (NIKI) reported a net loss of $1.4M in fiscal year 2025.
Niki BioSolutions, Inc. (NIKI) has a return on equity of -5.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Niki BioSolutions, Inc. (NIKI) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Niki BioSolutions, Inc. (NIKI) had $18.7M in total assets as of fiscal year 2025, including both current and long-term assets.
Niki BioSolutions, Inc. (NIKI) invested $353K in research and development during fiscal year 2025.
Niki BioSolutions, Inc. (NIKI) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Niki BioSolutions, Inc. (NIKI) had a return on assets of -7.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Niki BioSolutions, Inc. (NIKI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.3M as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Niki BioSolutions, Inc. (NIKI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.3M as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Niki BioSolutions, Inc. (NIKI) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Niki BioSolutions, Inc. (NIKI) reported a net loss of $1.4M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.